<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995032</url>
  </required_header>
  <id_info>
    <org_study_id>DMD02</org_study_id>
    <nct_id>NCT01995032</nct_id>
  </id_info>
  <brief_title>L-citrulline and Metformin in Duchenne's Muscular Dystrophy</brief_title>
  <official_title>&quot;A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show that the intake of L-citrulline and metformin improves
      muscle function and delay of progression in patients with Duchenne's muscular dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, placebo controlled study. The study
      medication consists of L-citrulline and metformin, respectively placebo given orally; 2.5 g
      L-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo
      will be administered 3 times daily. The duration of the study is 26 weeks and comprehends one
      screening and three study visits.

      Amendment 1: Amended eligibility criteria
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of motor function measure (MFM) D1 subscore (assessing standing and transfers)</measure>
    <time_frame>baseline to week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of MFM total score, the D2, and D3 MFM subscores</measure>
    <time_frame>baseline to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of six minute walking distance (6MWD)</measure>
    <time_frame>baseline to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quantitative muscle MRI (Magnetic Resonance Imaging) including muscle fat content (MFC) and T2 times of thigh muscles</measure>
    <time_frame>baseline to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the plasma/urine concentration for markers of muscle necrosis, oxidative stress, nitrosative stress, and change of microRNA (miRNA)</measure>
    <time_frame>baseline to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of quantitative muscle force (QMT) of knee extension and elbow flexion using hand held dynamometry (HHD)</measure>
    <time_frame>baseline to week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Duchenne's Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>750 mg metformin and 7.5 g L-citrulline daily p.o.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>750 mg metformin and 7.5 g L-citrulline daily p.o.</intervention_name>
    <arm_group_label>750 mg metformin and 7.5 g L-citrulline daily p.o.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Molecular diagnosis of DMD

          -  Patients 6.5 - 10 years of age at time of screening

          -  Ambulant

          -  Ability to walk 150 m in the 6 min walking distance (6MWT)

          -  D1 subdomain of the MFM scale &gt;40%

          -  stable treatment with steroids for &gt;6 months or steroid na√Øve patients

        Exclusion Criteria:

          -  Previous (3 months or less) or concomitant participation in another therapeutic trial

          -  Use of L-citrulline, L-arginine or metformin within the last 3 months

          -  Known individual hypersensitivity to L-citrulline or metformin

          -  known or suspected malignancy

          -  Other chronic disease or clinical relevant limitation of renal, liver, heart function
             according to discretion of investigator

          -  start of cortisone treatment or change in dosage &lt;6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>78 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne's muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

